Delineating the mechanisms that regulate NMDA receptors in mammallian neurons at Institute of Experimental Medicine of the Czech Academy of Sciences on FindAPhD.com

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities

Dr Martin Horák No more applications being accepted Funded PhD Project (Students Worldwide)

Prague Czechia Biochemistry Neuroscience Organic Chemistry

About the Project

Department of Neurochemistry: http://www.iem.cas.cz/en/research/departments/department-of-neurochemistry/

N-methyl-D-aspartate receptors (NMDARs) are a subclass of glutamate receptors that play an essential role in excitatory neurotransmission in the mammalian brain. NMDARs are tetrameric protein complexes composed of GluN1, GluN2, and GluN3 subunits, which can assemble in a variety of combinations. In this Ph.D. project, you will combine state-of-the-art molecular biology, biochemistry, immunocytochemistry and electrophysiology, with unique mice models in order to identify: i) which structural determinants in GluN subunits and NMDAR ligands regulate the surface delivery, mobility, and stability of NMDARs; and ii) how specific NMDARs and their ligands contribute to neurodegenerative conditions.

Candidate profile:

The candidate should have a M.Sc. (Mgr.) degree or equivalent in (bio)chemistry, molecular/cellular biology, medicine or physiology. We are seeking a person with a keen interest in basic neuroscience research.

How to apply: www.iem.cas.cz/phd

If you are interested, please visit the official website and submit the simple online application form. You can apply for up to 3 PhD positions. We are looking forward to hearing from you!

Funding Notes

After admission to the graduate program, the student usually receives an academic fellowship. In addition, the student becomes an IEM CAS employee and receives a salary (including payments towards social and healthcare insurance) and other benefits. This is financed by internal and grant funds of the IEM CAS.

References

Skrenkova et al. Scientific Reports 10(1):18576 (2020).
Hemelikova et al. Neuropharmacology 157:107671 (2019).
Skrenkova et al. Scientific Reports 9(1):12303 (2019).
Kaniakova et al. Neuropharmacology 140:217-232 (2018).
Skrenkova et al. Front Mol Neurosci 11:188 (2018).
Lichnerova et al. J Biol Chem 290(30):18379-90 (2015).
Kaniakova et al. J Biol Chem 287(31):26423-34 (2012).
Horak et al. J Neurosci 28(13):3500-9 (2008).